HRTT yields 285714.29% · ABBV yields 3.06%● Live data
📍 HRTT pulled ahead of the other in Year 1
Combined, HRTT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HRTT + ABBV for your $10,000?
Heart Tronics, Inc., a medical device company, engages in the research, development, and marketing of medical devices in the United States. Its medical devices are used to monitor and measure physiological signals in order to detect diseases that impact an individual's health. The company offers Fidelity 100 Monitor System, an integrated system in which its component Model 100 Patient Module collects, processes, and amplifies electrocardiogram (ECG) signals from that patient through a set of 10 electrodes that are wirelessly transmitted to the laptop computer. Its products in the development stage include Fidelity 350 Holter Monitor, an ambulatory Holter monitor that collects ECG data of arrhythmia and transient heart disease, while the patient carries out daily activities away from the physician's office or hospital. The company's products in the development stage also consist of Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device, which is used as an early-detection device by patients who desire to monitor their condition. Its products also include Cardiac Vest, a lightweight, close-fitting vest or undergarment made of stretchable material in which the electrodes are stitched into the fabric; and Fidelity 400 Intracardiac Monitor that applies its proprietary physiological signal acquisition and amplification technology to read intracardiac signals procured from intracardiac catheter. The company was formerly known as Signalife, Inc. and changed its name to Heart Tronics, Inc. in November 2008. Heart Tronics, Inc. was incorporated in 1987 is headquartered in Studio City, California.
Full HRTT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.